1
|
Beloglazkina A, Zyk N, Majouga A, Beloglazkina E. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction. Molecules 2020; 25:molecules25051211. [PMID: 32156064 PMCID: PMC7179467 DOI: 10.3390/molecules25051211] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2020] [Revised: 02/29/2020] [Accepted: 03/06/2020] [Indexed: 12/21/2022] Open
Abstract
This review presents the last decade of studies on the synthesis of various types of small-molecule inhibitors of the p53- Mouse double minute 2 homolog (MDM2) protein-protein interaction. The main focus is placed on synthetic approaches to such molecules, their cytotoxicity, and MDM2 binding characteristics.
Collapse
|
2
|
Furet P, Masuya K, Kallen J, Stachyra-Valat T, Ruetz S, Guagnano V, Holzer P, Mah R, Stutz S, Vaupel A, Chène P, Jeay S, Schlapbach A. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. Bioorg Med Chem Lett 2016; 26:4837-4841. [PMID: 27542305 DOI: 10.1016/j.bmcl.2016.08.010] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 08/03/2016] [Accepted: 08/05/2016] [Indexed: 11/27/2022]
Abstract
The p53-MDM2 interaction is an anticancer drug target under investigation in the clinic. Our compound NVP-CGM097 is one of the small molecule inhibitors of this protein-protein interaction currently evaluated in cancer patients. As part of our effort to identify new classes of p53-MDM2 inhibitors that could lead to additional clinical candidates, we report here the design of highly potent inhibitors having a pyrazolopyrrolidinone core structure. The conception of these new inhibitors originated in a consideration on the MDM2 bound conformation of the dihydroisoquinolinone class of inhibitors to which NVP-CGM097 belongs. This work forms the foundation of the discovery of HDM201, a second generation p53-MDM2 inhibitor that recently entered phase I clinical trial.
Collapse
Affiliation(s)
- Pascal Furet
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland.
| | - Keiichi Masuya
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Joerg Kallen
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | | | - Stephan Ruetz
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Vito Guagnano
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Philipp Holzer
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Robert Mah
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Stefan Stutz
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Andrea Vaupel
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Patrick Chène
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Sébastien Jeay
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| | - Achim Schlapbach
- Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland
| |
Collapse
|